3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
6
Phase 1
2
Phase 3
1
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Leukemia
10
Lymphoma
9
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Myelodysplastic Syndromes
7
Multiple Myeloma
7
Lymphoma, Non-Hodgkin
6
Leukemia, Myeloid, Acute
5
Hodgkin Disease
5
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Neoplasms, Plasma Cell
3
Myeloproliferative Disorders
3
Hematologic Neoplasms
3
Recurrence
2
Paraproteinemias
2
Myelodysplastic-Myeloproliferative Diseases
2
Lymphoproliferative Disorders
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large B-Cell, Diffuse
2
Leukemia, Myeloid, Chronic-Phase
2
Leukemia, Myeloid, Accelerated Phase
2
Congenital Abnormalities
2
Burkitt Lymphoma
2
Anemia, Aplastic
2
Waldenstrom Macroglobulinemia
1
Shwachman-Diamond Syndrome
1
Sezary Syndrome
1
Primary Immunodeficiency Diseases
1
Preleukemia
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Interventions
romidepsin
7
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
6
Vincristine
4
Gemcitabine
4
Doxorubicin
4
Cyclophosphamide
4
Prednisone
3
Lenalidomide
3
Azacitidine
3
10-propargyl-10-deazaaminopterin
3
pembrolizumab
2
ixazomib
2
fludarabine phosphate
2
copanlisib
2
Whole-Body Irradiation
2
Vitamin B 12
2
Peripheral Blood Stem Cell Transplantation
2
Nivolumab
2
Mycophenolic Acid
2
Folic Acid
2
Etoposide
2
Dexamethasone
2
Cyclosporine
2
Bortezomib
2
venetoclax
1
tislelizumab
1
tazemetostat
1
relatlimab
1
prednisolone phosphate
1
pomalidomide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Lymphoma, T-Cell, Peripheral
×
Alemtuzumab
×
Clear all
NCT00453427
2015-06-03
ACCAPELA
Ontario Clinical Oncology Group (OCOG)
Phase 1/2
Completed
20 enrolled